Item 1.01 Entry into a Material Definitive Agreement.

Amendment No. 1 to the Business Combination Agreement

On April 7, 2023, Chavant Capital Acquisition Corp., a publicly traded special purpose acquisition company incorporated under the laws of the Cayman Islands ("Chavant"), entered into Amendment No. 1 (the "BCA Amendment") to the previously disclosed Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Business Combination Agreement"), dated November 15, 2022, by and among Chavant, CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of Chavant ("Merger Sub"), and Mobix Labs, Inc., a Delaware corporation (the "Company" or "Mobix Labs"). Pursuant to the Business Combination Agreement, as further described in the Current Report on Form 8-K filed by Chavant with the Securities and Exchange Commission (the "SEC") on November 21, 2022 and attached thereto as Exhibit 2.1, at the Effective Time, Merger Sub will merge with and into Mobix Labs, with Mobix Labs surviving the merger as a wholly-owned direct subsidiary of Chavant (the "Merger" and, together with the other transactions related thereto, the "Proposed Transaction"). Capitalized terms used herein but not otherwise defined herein shall have the meanings assigned to them in the Business Combination Agreement.

Pursuant to the BCA Amendment, Chavant, Mobix Labs and Merger Sub have agreed, among other things, that certain securities issued subsequent to March 26, 2023, referred to as "Post-March 26 Financing Securities," will not be included in the calculation of the "Company Fully Diluted Number" under the Business Combination Agreement, with the effect that the Per Share Exchange Ratio will not be reduced on account of such issuances. "Post-March 26 Financing Securities" are defined in the BCA Amendment as any shares of (i) Company Common Stock or (ii) Company Common Stock issuable upon exercise or conversion of Company Warrants, Company Convertible Instruments or convertible debt, in each case, where such securities were issued for cash and in accordance with Sections 6.01(b)(iii) and (xix) of the Business Combination Agreement, as a result of, or in connection with, any private placement entered into by the Company after March 26, 2023. Except with the consent of Chavant (which consent shall not be unreasonably conditioned, withheld or delayed), Mobix Labs must use the proceeds of the issuance of any Post-March 26 Financing Securities to finance the ongoing business operations of the Company or to pay transaction expenses.

In addition, the BCA Amendment extended the Outside Date under the Business Combination Agreement from July 22, 2023 to November 22, 2023.

The foregoing description of the BCA Amendment does not purport to be complete and is qualified in its entirety by the full text of the BCA Amendment, which is attached hereto as Exhibit 2.1 and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On April 10, 2023, Chavant and Mobix Labs issued a press release announcing the filing by Chavant with the SEC of a registration statement on Form S-4 relating to the Proposed Transaction.

A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of Chavant under the Securities Act of 1933, as amended or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Important Information About the Proposed Transaction and Where to Find It

This Current Report on Form 8-K, including the exhibits filed herewith (the "Form 8-K"), relates to the Proposed Transaction between Mobix Labs and Chavant pursuant to the Business Combination Agreement. Chavant has filed a registration statement on Form S-4 with the SEC, which includes a preliminary prospectus and proxy statement of Chavant in connection with the Proposed Transaction, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Chavant shareholders as of a record date to be established for voting on the transaction. Chavant also will file other documents regarding the Proposed Transaction with the SEC.

Before making any voting decision, investors and security holders of Chavant are urged to read the registration statement, the proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with Chavant's solicitation of proxies for its shareholders' meeting to be held to approve the transaction, and all other relevant documents filed or that will be filed with the SEC in connection with the Proposed Transaction as they become available, because they will contain important information about Chavant, Mobix Labs and the Proposed Transaction.

Investors and securityholders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Chavant through the website maintained by the SEC at www.sec.gov.

The documents filed by Chavant with the SEC also may be obtained free of charge at Chavant's website at www.chavantcapital.com or upon written request to: Chavant Capital Acquisition Corp., 445 Park Avenue, 9th Floor New York, NY 10022.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS FORM 8-K, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS FORM 8-K. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.





Forward-Looking Statements

This Form 8-K contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this Form 8-K, including statements regarding the benefits of the Proposed Transaction and the anticipated timing of the completion of the Proposed Transaction, the products offered by Mobix Labs and the markets in which it operates, the expected total addressable markets for the products offered by Mobix Labs, the advantages of Mobix Labs' technology, Mobix Labs' competitive landscape and positioning, and Mobix Labs' growth plans, strategies and projected future results, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "plan," "targets," "projects," "could," "would," "continue," "forecast" or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Chavant and its management, and Mobix Labs and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to:

· the risk that the Proposed Transaction may not be completed in a timely manner

or at all, which may adversely affect the price of Chavant's securities;

· the risk that the Proposed Transaction may not be completed by Chavant's

deadline for the Proposed Transaction and the potential failure to obtain an

extension of the deadline for the Proposed Transaction if sought by Chavant;

· the failure to satisfy the conditions to the consummation of the Proposed


   Transaction, including the adoption of the merger agreement by the shareholders
   of Chavant, the satisfaction of the minimum cash amount following redemptions
   by Chavant's public shareholders;

· the lack of a third party valuation in determining whether or not to pursue the

Proposed Transaction;

· the occurrence of any event, change or other circumstance that could give rise

to the termination of the merger agreement;

· the effect of the announcement or pendency of the Proposed Transaction on Mobix

Labs' business relationships, performance, and business generally;

· risks that the Proposed Transaction disrupts current plans of Mobix Labs and

potential difficulties in Mobix Labs' employee retention as a result of the

Proposed Transaction;

· the outcome of any legal proceedings that may be instituted against Mobix Labs

or against Chavant related to the merger agreement or the Proposed Transaction;

· failure to realize the anticipated benefits of the Proposed Transaction;

· the inability to meet and maintain the listing of Chavant's securities (or the


   securities of the post-combination company) on Nasdaq;

· the risk that the price of Chavant's securities may be volatile due to a


   variety of factors, including changes in the highly competitive industries in
   which Mobix Labs plans to operate, variations in performance across
   competitors, changes in laws, regulations, technologies including transition to
   5G, global supply chain, U.S./China trade or national security tensions, and
   macro-economic and social environments affecting Mobix Labs' business and
   changes in the combined capital structure;

· the inability to implement business plans, forecasts, and other expectations

after the completion of the Proposed Transaction, and identify and realize

additional opportunities;

· the risk that Mobix Labs is unable to successfully commercialize its

semiconductor products and solutions, or experience significant delays in doing

so;

· the risk that Mobix Labs may never achieve or sustain profitability;

· the risk that Mobix Labs will need to raise additional capital to execute its

business plan, which may not be available on acceptable terms or at all;

· the risk that the post-combination company experiences difficulties in managing

its growth and expanding operations;

· the risks relating to long sales cycles, concentration of customers,

consolidation and vertical integration of customers, and dependence on

manufacturers and channel partners;

· the risk that Mobix Labs may not be able to consummate planned strategic

acquisitions, or fully realize anticipated benefits from past or future

acquisitions or investments;

· the risk that Mobix Labs' patent applications may not be approved or may take

longer than expected, and Mobix Labs may incur substantial costs in enforcing

and protecting its intellectual property;

· inability to complete the PIPE investment in connection with the Proposed

Transaction; and

· other risks and uncertainties set forth in the sections entitled "Risk Factors"


   and "Cautionary Note Regarding Forward-Looking Statements" in Chavant's Annual
   Report on Form 10-K for the year ended December, 31, 2022, which was filed with
   the SEC on March 31, 2023 (the "2022 Form 10-K"), as such factors may be
   updated from time to time in Chavant's filings with the SEC, the registration
   statement and the proxy statement/prospectus contained therein. These filings
   identify and address other important risks and uncertainties that could cause
   actual events and results to differ materially from those contained in the
   forward-looking statements.

Nothing in this Form 8-K should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Chavant nor Mobix Labs gives any assurance that either Chavant or Mobix Labs or the combined company will achieve its expected results. Neither Chavant nor Mobix Labs undertakes any duty to update these forward-looking statements, except as otherwise required by law.

Participants in the Solicitation

Mobix Labs and Chavant and their respective directors and officers and other members of management may, under SEC rules, be deemed to be participants in the solicitation of proxies from Chavant's stockholders with the Proposed Transaction and the other matters set forth in the registration statement. Information about Chavant's directors and executive officers is set forth in Chavant's filings with the SEC, including Chavant's 2022 Form 10-K. Additional information regarding the direct and indirect interests, by security holdings or otherwise, of those persons and other persons who may be deemed participants in the Proposed Transaction may be obtained by reading the proxy statement/prospectus regarding the Proposed Transaction when it becomes available. You may obtain free copies of these documents as described above under "Important Information About the Proposed Transaction and Where to Find It."





No Offer or Solicitation

This Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Transaction and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy, sell or solicit any securities or any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be deemed to be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit
  No.      Description

  2.1        Amendment No. 1 to the Business Combination Agreement, dated as of
           April 7, 2023, by and among Chavant Capital Acquisition Corp., CLAY
           Merger Sub II, Inc. and Mobix Labs, Inc. (incorporated by reference to
           Exhibit 2.2 to the Registration Statement on Form S-4 filed by Chavant
           Capital Acquisition Corp. on April 10, 2023).
  99.1       Press Release, dated April 10, 2023.
104        Cover Page Interactive Data File (embedded with the Inline XBRL
           document).

© Edgar Online, source Glimpses